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Nasopharyngeal angiofibroma is a vascular benign 
tumor that affects young men, and surgery is the treatment 
of choice. Endoscopic surgery has been used to excise 
tumors in their initial stages, when there is no evidence 
of residual or recurrent disease. Aim: The aim of this 
study is to evaluate the endoscopic approach preceded by 
tumor embolization as treatment option for stages II to III 
angiofibroma. Treatment morbidity was evaluated through: 
surgery duration, hospital stay after surgery, the need for 
blood transfusion, complications, the time span between 
preoperative embolization and surgery, and tumor recurrence. 
Methods: A prospective study was carried out with nine 
patients treated at the Fortaleza General Hospital SESA/SUS 
from October 2001 through November 2004. Conclusion: 
Based on the results, we may conclud that the endoscopic 
approach, when preceded by embolization, is effective 
to treat angiofibromas in their initial stages, with reduced 
postoperative morbidity.
Keywords: endoscopic approach, nasopharyngeal 
angiofibroma.
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INTRODUCTION
Nasal angiofibroma is a vascular tumor that, despite 
being histologically benign, it is locally invasive and bears 
a high rate of persistence and recurrence. It corresponds 
to 0.5% of head and neck tumors1. Its classical treatment is 
surgery; however there are cases in which we may indicate 
radiotherapy2 or even, hormone therapy. 
There are descriptions of atypical locations for this 
tumor, in sites such as the lacrimal sac, paranasal region, 
and limited to the sphenoid sinus3. Notwithstanding, the 
most common location is the one limited to he rhinophar-
ynx and nasal cavities. 
Its clinical staging is done through the Radkowski, 
rence of tumors to the infra-temporal fossa or the cavern-
ous sinuses10.
The endoscopic approach is, indubitably a sound 
alternative, because despite being less aggressive to the 
patient, it causes less morbidity11, minimum bleeding, 
less operative time and greater efficacy7,12, moreover, it 
brings about less transoperative complications and better 
postoperative function13. When properly indicated, the 
procedure bears low recurrence rates2,9, being the first 
treatment option. 
Aiming at assessing the endoscopic approach for 
the treatment of nasal angiofibromas in its initial stages, 
in regards to operative morbidity, residual disease and re-
currence, we studied patients who were surgically treated 
because of this tumor at the Fortaleza General Hospital 
- SESA/SUS.
MATERIAS AND METHODS
In order to assess the results obtained from the nasal 
endoscopic resection of nasal angiofibromas in patients 
who underwent prior tumor embolization, we carried out 
a prospective analysis of 9 patients who were operated at 
the Fortaleza General Hospital - SESA/SUS, from October 
of 2001 to November of 2004, by the same surgeon, under 
general anesthesia and by the same surgical approach. 
Only one patient underwent a combined procedure by 
nasal endoscopy and video-assisted sublabial transmaxil-
lary procedure (patient number seven). All patients were 
in surgical classes II and III (according to Chandler’s 
classification4) (Chart 1).
The patients from the present study were between 
9 and 20 years of age, with a medical history of epistaxis 
and nasal obstruction for about 9.5 months in average (1 
to 36 months). The most prevalent tumor stage was Stage 
II (8 patients), however 1 patient was in stage III (Table 1). 
They all underwent embolization prior to surgery, having 
an average of 4.7 days between embolization and surgery 
Chart 1. Staging according to Chandler (1984).
• Stage I - limited to the nasopharynx;
• Stage II - extends to the nasal cavity and/or the sphenoidal sinus;
• Stage III - extension to one of the following: maxillary sinus, eth-
moidal sinus, pterigomaxillary and infratemporal fossa, medial orbit 
and/or cheek;
• Stage IV - intracranial extension and/or to the lateral orbit.
Fisch or Chandler4 classification system (Chart - 1).
Its surgical treatment may be carried out endoscopi-
cally or through an open procedure, the latter is through 
the transpalatine, transmaxillary (involving the mid-facial 
degloving approach, Weber-Fergusson procedure and 
lateral rhinotomy), and cranio-facial technique, when 
there is extensive intracranial tumor invasion. Currently it 
is advisable to perform a selective tumoral embolization 
prior to proceeding with any of the techniques known - in 
order to facilitate surgical access. 
Studies have shown that the endoscopic procedure 
is effective only for the total removal of small and inter-
mediary size tumors5-8; notwithstanding, there are studies 
that favor even the removal of tumors that extend to the 
pterigoid fossa and limited to the cranial fossa9. However, 
the debate remains, because studies have shown recur-
Table 1. Relationship between patients, clinical stage, age and disease evolution time.
Pac Stage Age Time of evolution
1 II - Nasopharynx and right nasal cavity. 09 years 02 months
2 II - Nasopharynx with closure of the Rosemüller fossa. 16 years 06 months
3 II - Nasopharynx, right nasal cavity and sphenoid sinus. 20 years 36 months
4 II - Left nasal cavity, sphenoid sinus and nasopharynx. 15 years 12 months
5 II - Left Pterigopalatine Fossa, extending to the cavum and ipsilateral nasal cavities. 15 years 11 months
6
II - Left nasal cavity, extending posteriorly to the choanas, totally occluding them, without cleavage of 
nasopharynx soft tissue.
15 years 06 months
7
III - Nasopharynx, right nasal cavity, right maxillary sinus, sphenoid sinus, ethmoid cells and medial 
orbit.
11 years 05 months
8 II - Right Nasopharynx and ethmoid sinus bilaterally. 18 years 07 months
9 II - Right Nasopharynx and right sphenoid sinus. 18 years 01 mês
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Figure 1. Pre-embolization angiofibroma arteriography - maxillary artery 
branching off to the tumor.
Figure 2. Post-embolization angiography - maxillary artery without 
tumor branches.
(from 2 to 7 days) (Figures 1 and 2). Balanced general 
anesthesia was the type used in all the cases. The surgical 
procedures were assessed as to the operative time, need 
for blood transfusion either during or after the procedure, 
complications, hospital stay after surgery, the time span 
between embolization and the surgical procedure, and 
tumor recurrence. The latter was assessed through CT-Scan 
and/or flexible nasal fibroscopy in the postoperative fol-
low up (which varied from one and thirty four months). 
The intraoperative bleeding parameters were the volume 
of liquid in the vacuum container (considering the volume 
of saline solution used during surgery) as well as clinical 
parameters such as reflex tachycardia or hypo perfusion. 
Blood parameters were assessed both in the pre and 
post operative, and for this study we computed only the 
levels of hemoglobin. Prior to embolization, all patients 
were submitted to arteriography. Embolization was car-
ried out through a femoral puncture and introduction of 
a 6F catheter using Seldinger’s technique  (a 6F catheter 
guided by a 035 hydrophilic guide) for a super-selective 
catheterization of the artery involved (external carotid ar-
tery); and with a Renegade® 2.3F micro catheter aided by 
a 014 Terumo® guide for a super-selective  cauterization 
of the tumor nurturing vessels. Embolization was effec-
tive by using 150µ to 250µ and from 250µ to 350µ PVA 
particles (polyvinyl-alcohol). Embolization complications 
seen were from the simplest ones such as headaches, 
trismus, localized pain, fever, rhinorrhea, all the way up 
to major complications. All patients had their diagnosis 
confirmed by pathology.
RESULTS
Embolization complications were clear in 5 patients 
(TMJ pain was the most frequently found complication). 
Average surgery time was of 102 minutes (between thirty 
minutes and two hours and forty-five minutes) (Table 2). 
Only one patient required intraoperative blood transfu-
Table 2. Relationship between patients, time span between embolization and surgery, complications and blood transfusion needs and surgery 
duration.
Patient Embolization and surgery time Embolization complications Surgery Trans or postoperative transfusion
1 04 days Vomit and TMJ pain 00:30 h No
2 06 days TMJ pain 01:35 h No
3 03 days Absent 02:30 h No
4 04 days Headaches 02:30 h No
5 06 days TMJ pain 01:15 h No
6 07 days Absent 01:45 h No
7 07 days Absent 02:45 h Yes (300ml)
8 02 days Absent 01:00 h No
9 04 days
Trismus and right temporal 
headache
01:30 h No
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sion, and this same patient was the only one who had a 
dropping in his hemoglobin levels when pre-op values 
were compared to postoperative ones (it went from 16 
to 14mg/dl, even after transfusion). The other patients 
kept hemoglobin levels approximately stable (variation of 
approximately only 1mg/dl). Eight days was the average 
hospital stay in the postoperative time (between one and 
seventeen days). Only 3 patients required nasal packing 
in the postop. There were no surgical complications. 
Follow up was carried out through CT-Scan or flexible 
nasal fibroscopy (Figures 3 and 4) for a period of one to 
thirty-seven months, without evidence of residual disease 
or recurrence in none of the cases (Table 3). 
DISCUSSION
Nasal angiofibroma is a fairly common tumor in 
young people, thus presenting peculiar characteristics as 
to its therapeutic aspects. Its treatment is almost exclusively 
surgical, and all the therapeutic weaponry should be used 
in order to promote patients’ fast recovery, sparing them 
Table 3. Relationship between patients and duration of nasal packing, post-operative hospital stay, tumor recurrence and follow up time.
Patient Nasal packing Postoperative hospital stay Tumor recurrence Follow up time
1 No 06 days Absent -CT and nasal fibroscopy 12 months
2 No 13 days Absent - CT and nasal fibroscopy 18 months
3 02 days 07 days Absent - nasal fibroscopy 26 months
4 No 06 days Absent - nasal fibroscopy 19 months
5 No 10 days Absent - CT and nasal fibroscopy 18 months
6 04 days 11 days Absent -nasal fibroscopy 09 months
7 04 days 17 days Absent -nasal fibroscopy 10 months
8 No 01 dia Absent -nasal fibroscopy 37 months
9 No 02 days Absent -nasal fibroscopy 03 months
Figure 3. Nasofibroscopy showing the tumor in the right nasal cavity 
- angiofibroma in the center.
Figure 4. Post-operative nasofibroscopy - no tumor in the right nasal 
cavity.
as much as possible from school or work absence, thus 
reducing the social repercussions of the disease. Our se-
ries corroborated such behavior as to age of onset, and 
all the patients were young. Endoscopic nasal surgery is 
not only feasible, but also a very efficient alternative in 
the treatment of these tumors it their initial stages, when 
it is less aggressive and dos not impair much the patients’ 
postop recovery. Although it has been well established 
that one hour more of surgery time doubles the inci-
dence of infection and it is certainly one more factor that 
increases trauma and its repercussions, operative time 
is still discussed. There is no relation between surgery 
duration and postoperative complications, death or long 
term survival14. Notwithstanding, it is also known that the 
longer the surgery takes, greater are the alterations that 
happen in body homeostasis during surgical trauma. Thus 
the need to improve techniques in order to spend less time 
in surgery and reduce the risk to the patient’s life. Endo-
scopic surgery was developed in order to provide a less 
invasive approach and thus cause less harm to patients. 
Since this is a nasal approach, endoscopy brought about 
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not only less invasion, but also better cosmetic results and 
less surgery time. This was seen in the present study, in 
which average surgical time was of 102 minutes, matching 
reports considered satisfactory in the literature7.
The short hospital stay after surgery also contributes 
to patients’ fast recovery, reflecting the lack of complica-
tions and readmissions15. Endoscopic surgery has a great 
advantage because it requires less rehabilitation days after 
surgery, requiring less days of hospitalization and is less 
subject to hospital infections.
However, since it is a very specific technique, nasal 
endoscopic surgery has an important disadvantage - it re-
quires a bloodless operating field - because any amount of 
blood may prevent a good visualization and thus preclude 
the surgical approach. 
Tumor embolization is a technique that contributes 
much to nasal angiofibroma endoscopic surgery, having 
a critical participation in its vascular composition and 
making the surgery more accessible and visible for the 
surgeon. Endoscopic surgery has a very important advan-
tage, which is the fact that it preserves both the anatomy 
and physiology of the nose, and the prior tumor embo-
lization contributes to a better identification of structures 
during surgery, without considerable hemorrhage, thus 
making the procedure easier. Thus, prior embolization 
contributes to reduce surgical morbidity. Studies state 
that the ideal time between tumor embolization and the 
endoscopic surgical procedure should be around 24 to 72 
hours5; however, in our department this time has varied 
within an average of 4.7 days, with effective embolization 
of all the tumors and performance of all the endoscopic 
procedures without problems. The clinical observation in 
our clinic, considering the tumoral embolization of over 
30 angiofibromas operated, not only through endoscopy, 
but also through open surgery, it has been between 5 and 
7 days, after embolization as the ideal period for surgery, 
having seen that the tumor becomes more fibrous, with 
areas of necrosis and with much less bleeding than those 
operated with less than 3 days of wait, thus making the 
surgeon’s life a lot easier. We also noticed that after 7 days, 
bleeding returned, this time it was induced by collateral 
circulation created to nurture the tumor. These findings 
are in disagreement with the literature, in which most of 
the authors use resorbable particles such as gelfoam or 
dextran microspheres or short duration non-absorbable 
such as Ivalon, ITC contour or Terbal. In our department 
we use polyvinyl-alcohol particles, which last longer and 
is more efficient.
Complications and the need for blood transfusion 
also indicate how severe the surgery should be, as well 
as the aggression caused to the patient’s body. Transop-
erative transfusion indicates poor prognosis, reducing 
postoperative survival14. The endoscopic surgeries of the 
present study did not show severe complications in any 
of the patients, there were only minor complications from 
the embolization, and only one case which needed blood 
transfusion. As it happens to all invasive procedures, em-
bolization also bears some risks, which should be duly 
explained to the patients, and all care should be taken in 
order to avoid them: the most significant risks are blind-
ness - due to the occlusion of the ophthalmic artery, or 
due to occlusion of the middle cerebral artery through the 
collateral circulation. 
CONCLUSION
With the data presented in this study, we may con-
clude that the endoscopic approach is a safe procedure 
to resect nasal angiofibromas in its initial stages, having 
seen its low morbidity and great effectiveness, with total 
tumor removal without recurrence rates. However, it is 
worth highlighting that such success is primarily due to 
tumor embolization prior to surgery, which makes the 
procedure safe, fast and effective. However, since the 
number of patients is so small, and recent cases have 
such a short follow up time, we intend to increase our 
numbers and the assessment time for a more complete 
and accurate study. 
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